5,6,7,8-Tetrahydropyrido[3,2-d]pyrimidine | 1211585-58-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶并嘧啶类
• 英文名称: 5,6,7,8-Tetrahydropyrido[3,2-d]pyrimidine
• CAS: 1211585-58-8
• 化学式: C₇H₉N₃
• 分子量: 135.17
• InChiKey: VRUDHVVJIWFTGM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS<br/>[FR] COMPOSÉS BENZOLACTAMES UTILISÉS EN TANT QU'INHIBITEURS DE PROTÉINE KINASE
  申请人：OTSUKA PHARMA CO LTD

  公开号：WO2017068412A1

  公开（公告）日：2017-04-27

  The invention provides a compound of formula (0): or a pharmaceutically acceptable salt, N-oxide or tautomer thereof. The compounds are inhibitors of ERK 1/2 kinases and will be useful in the treatment of ERKl/2-mediated conditions. The compounds are therefore useful in therapy, in particular in the treatment of cancer.

  该发明提供了一个化合物，其化学式为(0)：或其药学上可接受的盐、N-氧化物或互变异构体。这些化合物是ERK 1/2激酶的抑制剂，并将在治疗ERKl/2介导的疾病中发挥作用。因此，这些化合物在治疗中特别是在癌症治疗中是有用的。
• Guanidine derivatives
  申请人：Breu Volker

  公开号：US20070123510A1

  公开（公告）日：2007-05-31

  The invention relates to the guanine derivatives of general formula (I), and to hydrates or solvents thereof, for use as neuropeptide FF receptor antagonists in the treatment of pains and hyperalgesia, of withdrawal symptoms of addiction to alcohol, psychotropic drugs or nicotine and in the prevention of or recovery from these addictions, for the regulation of insulin release, food intake, memory functions, blood pressure, electrolyte and energy metabolism, and in the treatment of urinary incontinence.

  该发明涉及通式（I）的鸟嘌呤衍生物，以及其水合物或溶剂，用作神经肽FF受体拮抗剂，用于治疗疼痛和过敏症，戒酒症状，对酒精、精神药物或尼古丁成瘾的预防或康复，用于调节胰岛素释放、食物摄入、记忆功能、血压、电解质和能量代谢，以及治疗尿失禁。
• 2,4-Diaminopyrimidine compounds useful as immunosuppressants
  申请人：——

  公开号：US20030191307A1

  公开（公告）日：2003-10-09

  Novel compounds according to the formula 1 and pharmaceutically acceptable salts, solvates, or hydrates thereof; wherein each occurrence of A is independently selected from CH or N; X is selected from the group consisting of —CH 2 —, —O—, —NH—, (C 1 -C 6 )alkylamino-, (C 1 -C 6 )alkylaminocarbonylamino-, (C 1 -C 6 )alkylcarbonylamino-, (C 1 -C 6 )alkylsulfonylamino-, phenylsulfonylamino-, carbonyl, —NH—C(O)—, —N(C 1 -C 6 )alkyl-C(O)—, —S(O) y — where y is 0, 1 or 2, and; n in —(CH 2 ) n — is 1, 2 or 3; and R 1 , R 2 , and R 3 are as described herein; pharmaceutical compositions that including these compounds, and methods for the treatment of autoimmune disease, inflammation, allergy, transplant rejection, and other circumstances where administration of an immunosuppressive agent is of therapeutic benefit.

  根据公式1及其药学上可接受的盐、溶剂或水合物，制备了新的化合物；其中A的每次出现独立地选自CH或N；X选自以下群体：—CH2—、—O—、—NH—、(C1-C6)烷基氨基、(C1-C6)烷基氨基甲酰氨基、(C1-C6)烷基羧酰氨基、(C1-C6)烷基磺酰氨基、苯基磺酰氨基、羰基、—NH—C(O)—、—N(C1-C6)烷基-C(O)—、—S(O)y—，其中y为0、1或2，而—(CH2)n—中的n为1、2或3；R1、R2和R3如本文所述；包括这些化合物的药物组合物，以及用于治疗自身免疫性疾病、炎症、过敏、移植排斥以及其他需要免疫抑制剂治疗的情况的方法。
• [EN] CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE<br/>[FR] CERTAINES AMINO-PYRIDAZINES, COMPOSITIONS CONTENANT CES DERNIÈRES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：CYTOKINETICS INC

  公开号：WO2011133888A1

  公开（公告）日：2011-10-27

  Provided are compounds of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and m are as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

  提供的是公式(I)的化合物或其药学上可接受的盐，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、X和m的定义如本文所述。还提供了一种药学上可接受的组合物，包括公式I的化合物或其药学上可接受的盐。还提供了使用公式I的化合物或其药学上可接受的盐的方法。
• AMINO-PYRIMIDINE SKELETAL MUSCLE MODULATORS
  申请人：Cytokinetics, Inc.

  公开号：US20210045997A1

  公开（公告）日：2021-02-18

  Provided are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , X and mare as defined herein. Also provided is a pharmaceutically acceptable composition comprising a compound of Formula I, or a pharmaceutically acceptable salt thereof. Also provided are methods of using a compound of Formula I, or a pharmaceutically acceptable salt thereof.

  提供的是公式I的化合物：或其药学上可接受的盐，其中R1，R2，R3，R4，R5，R6，R7，R8，R9，X和m的定义如此。还提供了一种药学上可接受的组合物，包括公式I的化合物或其药学上可接受的盐。还提供了使用公式I的化合物或其药学上可接受的盐的方法。